Difference between revisions of "Oropharyngeal cancer, HPV-positive"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Twitter: " to "frameless|upright=0.1") |
Warner-admin (talk | contribs) m (Text replacement - "https://www.ncbi.nlm.nih.gov/pubmed/" to "https://pubmed.ncbi.nlm.nih.gov/") |
||
(42 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
− | + | <span id="BackToTop"></span> | |
− | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | |
− | + | [[#top|Back to Top]] | |
− | + | </div> | |
− | + | {{#lst:Editorial board transclusions|hn}} | |
− | + | '''Note: this page has regimens which are specific to oropharyngeal cancer that is human papilloma virus (HPV) positive. Please see the [[head and neck cancer]] page for other regimens.''' | |
− | |} | ||
− | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Line 13: | Line 11: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | = | + | =Guidelines= |
+ | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | ||
+ | ==ASCO== | ||
+ | *'''2019:''' Adelstein et al. [https://doi.org/10.1200/jco.19.00441 Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion] [https://pubmed.ncbi.nlm.nih.gov/31021656/ PubMed] | ||
+ | |||
+ | ==EHNS/ESMO/ESTRO== | ||
+ | *'''2020:''' Machiels et al. [https://doi.org/10.1016/j.annonc.2020.07.011 Squamous cell carcinoma of the oral cavity, larynx, '''oropharynx''' and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/33239190 PubMed] | ||
+ | |||
+ | ==NCCN== | ||
+ | *''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437 NCCN Guidelines - Head and Neck Cancers].'' | ||
+ | |||
+ | =Definitive therapy= | ||
==Cisplatin & RT {{#subobject:c7061f|Regimen=1}}== | ==Cisplatin & RT {{#subobject:c7061f|Regimen=1}}== | ||
− | + | Cisplatin & RT: Cisplatin & '''<u>R</u>'''adiation '''<u>T</u>'''herapy | |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Regimen variant #1, 100 mg/m<sup>2</sup> q3wk x 2 {{#subobject:b44282|Variant=1}}=== | |
− | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | |
− | RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy | + | !style="width: 20%"|Study |
− | === | + | !style="width: 20%"|Dates of enrollment |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: | + | !style="width: 20%"|Comparator |
− | !style="width: | + | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
− | !style="width: | ||
− | !style="width: | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6541928/ Gillison et al. 2018 (RTOG 1016)] |
− | |style="background-color:#1a9851"|Phase | + | |2011-2014 |
− | |Cetuximab & RT | + | |style="background-color:#1a9851"|Phase 3 (C) |
+ | |[[#Cetuximab_.26_RT_999|Cetuximab & RT]] | ||
| style="background-color:#91cf60" |Seems to have superior OS | | style="background-color:#91cf60" |Seems to have superior OS | ||
|- | |- | ||
|} | |} | ||
− | ==== | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | *[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on | + | ====Chemotherapy==== |
− | *Concurrent [[External_beam_radiotherapy|radiation therapy]] | + | *[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once per day on days 1 & 22 |
− | + | ====Radiotherapy==== | |
− | ''' | + | *Concurrent [[External_beam_radiotherapy|radiation therapy]] 200 cGy fractions x 35 fractions (total dose: 7000 cGy), given 6 times per week |
− | + | '''6-week course''' | |
− | === | + | </div></div><br> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | !style="width: | + | ===Regimen variant #2, 100 mg/m<sup>2</sup> q3wk x 3 {{#subobject:aca3c0|Variant=1}}=== |
− | !style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | !style="width: | + | !style="width: 20%"|Study |
− | !style="width: | + | !style="width: 20%"|Dates of enrollment |
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6319250/ Mehanna et al. 2018 (De-ESCALaTE HPV)] |
− | |style="background-color:#1a9851"|Phase | + | |2012-2016 |
− | |Cetuximab & RT | + | |style="background-color:#1a9851"|Phase 3 (C) |
+ | |[[#Cetuximab_.26_RT_999|Cetuximab & RT]] | ||
| style="background-color:#1a9850" |Superior OS | | style="background-color:#1a9850" |Superior OS | ||
|- | |- | ||
|} | |} | ||
− | ==== | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | *[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on | + | ====Chemotherapy==== |
− | *Concurrent [[External_beam_radiotherapy|radiation therapy]] | + | *[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once per day on days 1, 22, 43 |
− | + | ====Radiotherapy==== | |
− | ''' | + | *Concurrent [[External_beam_radiotherapy|radiation therapy]] 200 cGy fractions x 35 fractions (total dose: 7000 cGy), given 6 times per week |
+ | '''9-week course''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # '''RTOG 1016:''' Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2018 Nov 15. | + | # '''RTOG 1016:''' Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019 Jan 5;393(10166):40-50. Epub 2018 Nov 15. Erratum in: Lancet. 2020 Mar 7;395(10226):784. [https://doi.org/10.1016/S0140-6736(18)32779-X link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6541928/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30449625/ PubMed] [https://clinicaltrials.gov/study/NCT01302834 NCT01302834] |
− | # '''De-ESCALaTE HPV:''' Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J; De-ESCALaTE HPV Trial Group. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2018 Nov 15. | + | # '''De-ESCALaTE HPV:''' Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J; De-ESCALaTE HPV Trial Group. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019 Jan 5;393(10166):51-60. Epub 2018 Nov 15. [https://doi.org/10.1016/S0140-6736(18)32752-1 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6319250/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30449623/ PubMed] ISRCTN33522080 |
− | |||
[[Category:Head and neck cancer regimens]] | [[Category:Head and neck cancer regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Head and neck cancers]] | [[Category:Head and neck cancers]] |
Latest revision as of 12:00, 6 July 2024
Section editor | Page editor | ||
---|---|---|---|
Jennifer H. Choe, MD, PhD Vanderbilt University Nashville, TN, USA |
C. Beau Hilton, MD Vanderbilt University Nashville, TN, USA |
Note: this page has regimens which are specific to oropharyngeal cancer that is human papilloma virus (HPV) positive. Please see the head and neck cancer page for other regimens.
1 regimens on this page
2 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ASCO
- 2019: Adelstein et al. Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion PubMed
EHNS/ESMO/ESTRO
- 2020: Machiels et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Head and Neck Cancers.
Definitive therapy
Cisplatin & RT
Cisplatin & RT: Cisplatin & Radiation Therapy
Regimen variant #1, 100 mg/m2 q3wk x 2
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Gillison et al. 2018 (RTOG 1016) | 2011-2014 | Phase 3 (C) | Cetuximab & RT | Seems to have superior OS |
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV once per day on days 1 & 22
Radiotherapy
- Concurrent radiation therapy 200 cGy fractions x 35 fractions (total dose: 7000 cGy), given 6 times per week
6-week course
Regimen variant #2, 100 mg/m2 q3wk x 3
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Mehanna et al. 2018 (De-ESCALaTE HPV) | 2012-2016 | Phase 3 (C) | Cetuximab & RT | Superior OS |
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV once per day on days 1, 22, 43
Radiotherapy
- Concurrent radiation therapy 200 cGy fractions x 35 fractions (total dose: 7000 cGy), given 6 times per week
9-week course
References
- RTOG 1016: Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019 Jan 5;393(10166):40-50. Epub 2018 Nov 15. Erratum in: Lancet. 2020 Mar 7;395(10226):784. link to original article contains dosing details in abstract link to PMC article PubMed NCT01302834
- De-ESCALaTE HPV: Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J; De-ESCALaTE HPV Trial Group. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019 Jan 5;393(10166):51-60. Epub 2018 Nov 15. link to original article contains dosing details in abstract link to PMC article PubMed ISRCTN33522080